



04-30-01

CPA/1623 \$

Box See Patent

Attorney Docket: 237/023

#14
5/30/01

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 02 2001

TECH CENTER 1600/2900

BOX CPA
Commissioner for Patents
Washington, D.C. 20231Attorney Docket No.: 237/023
First Named Inventor: Mumpeer, Russ
Prior Application Information:
Serial No.: 09/149,721
Examiner: H. Owens, Jr.
Art Unit: 1623

05/02/2001 GTEFFERA 00000001 09149721
01 FC:231 355.00 OP
02 FC:203 261.00 OP
03 FC:202 120.00 OP
04 FC:204 135.00 OP

CONTINUED PROSECUTION APPLICATION (CPA) UNDER 37 CFR § 1.53(D)

This is a Request for filing a Continuation or Divisional Application, under 37 CFR § 1.53(d) (Continued Prosecution Application (CPA)) of prior application Serial No. 09/149,721 filed on September 8, 1998 entitled **Hydrophobic Glycosylamine Derivatives, Compositions, and Methods of Use** by Russ Mumpeer and Frank Tagliaferri, which remains the same for this Continuing Application.

The above-identified application in which no payment of Issue Fee, abandonment of, or termination of proceedings has occurred, is hereby expressly abandoned as of the filing date of this request for a CPA. Please use all the contents of the prior application file wrapper, including the drawings, as the basic papers for the new application.

1. Enter the Amendment After Final under 37 CFR § 1.116 previously filed on _____ but unentered, in the prior application.
2. A Preliminary Amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application. Pursuant to 37 CFR § 1.53(d)(4) please delete the following inventors named in the prior application:
4. A new Power of Attorney or Authorization of Agent is enclosed.
5. Information Disclosure Statement with PTO-1449; copy of citations.
6. Applicant claims small entity status pursuant to 37 CFR 1.27.
7. Request for extension of time to respond is being filed in the prior application to maintain copendency.

LA-192006.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL533096671US
Express Mail Label No.April 26, 2001
Date of DepositLaura Murphy
Name of Person Mailing Paper

Signature of Person Mailing Paper

Patent
Attorney Docket:237/023

8. Request and Certification under 35 U.S.C. § 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35

9. Also enclosed: DNA SEQUENCE REQUIREMENT.

The filing fees due in accordance with 37 CFR § 1.16 have been calculated as shown below:

BASIC FILING FEE:					\$710.00
Total Claims	49	-	20	=	29 x \$18.00 522.00
Independent Claims	6	-	3	=	3 x \$80.00 \$240.00
Multiple Dependent Claims	\$270	(if applicable)		<input checked="" type="checkbox"/>	\$270.00
TOTAL OF ABOVE CALCULATION					\$1,742.00
Reduction by ½ for Filing by Small Entity.				<input checked="" type="checkbox"/>	\$871.00
Other Fees (itemize)					\$0.00
TOTAL FEES DUE HEREWITH					\$871.00

- A check is enclosed in the amount of \$871.00 is enclosed.
- Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of _____.
- The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for any fees required under 37 CFR §§ 1.16, 1.17, 1.21 and 1.445 that are not covered, in whole or in part, by any amounts enclosed herewith and to credit any overpayments to said Deposit Account No. **12-2475**.

Please send all correspondence to Customer Number 22249:



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
Suite 4700
633 W. Fifth Street
Los Angeles, CA 90071
(213) 489-1600

Please direct all telephone calls to

Respectfully submitted,

LYON & LYON LLP

By: 
David A. Randall
Reg. No. 37,217

Dated: April 26, 2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- DIPE JC
APR 26 2001
- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
 - 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
 - 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
 - 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
 - 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
 - 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
 - 7. Other: _____

RECEIVED

MAY 02 2001

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". TECH CENTER 1600/2900
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE